Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors

Autor:	Angelo J. Gemma, Jill N. Allen, Andrew X. Zhu, James C. Cusack, Christine E. Eyler, Theodore S. Hong, Jeffrey W. Clark, Darrell R. Borger, David P. Ryan, Jennifer Y. Wo, Eunice L. Kwak, Harvey J. Mamon, David H. Berger, Paul C. Shellito, Lipika Goyal, Kevin M. Haigis, Hui Zheng, Henning Willers, David W. Rattner
Rok vydání:	2018
Předmět:	Cancer Research Colorectal cancer business.industry Mutant Locally advanced medicine.disease 03 medical and health sciences Leukemia chemistry.chemical_compound 0302 clinical medicine medicine.anatomical_structure Oncology chemistry Fluorouracil hemic and lymphatic diseases 030220 oncology & carcinogenesis medicine Cancer research 030212 general & internal medicine Midostaurin business Sensitization medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:e15674-e15674
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.e15674
Popis:	e15674Background: RAS mutations confer radiation resistance in rectal cancer, with very low pCR rates, below 5%. Midostaurin is an oral, multi-target TKI, FDA-approved for FLT3 mutated leukemia, th...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::103ed8c3aac96e5a54e80f99861d6745 https://doi.org/10.1200/jco.2018.36.15_suppl.e15674 Zobrazit plný text záznamu